OpenLB
Open Library of Bioscience
Advanced Search
Leukemia research reports
2022;17 100324.

Monoclonal antibody-based therapies for Waldenström's macroglobulinemia.

Despina Fotiou, Foteini Theodorakakou, Efstathios Kastritis
Author Information
  1. Despina Fotiou: Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece.
  2. Foteini Theodorakakou: Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece.
  3. Efstathios Kastritis: Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece.
PMID: 35572915 DOI: 10.1016/j.lrr.2022.100324

Abstract

Monoclonal antibodies have established an important role in the treatment armamentarium of hematological malignancies, including Waldenström's macroglobulinemia. Rituximab, an anti-CD20 monoclonal antibody, is established as standard therapy for this unique low grade lymphoma, due to its effectiveness and safety as monotherapy, in combination with chemotherapy or other targeted therapies in WM. Newer monoclonal antibodies, targeting CD20 or other surface antigens, have shown to be effective in patients with WM. In the current review we attempt to provide an overview of the mechanisms of action of monoclonal antibodies and discuss clinical evidence that support their use in WM and their therapeutic potential.

Keywords

Monoclonal antibodies Rituximab Waldenström's macroglobulinemia

References

  1. Semin Oncol. 2003 Apr;30(2):110-5 [PMID: 12720118]
  2. Ann Oncol. 2004 Oct;15(10):1481-3 [PMID: 15367407]
  3. BioDrugs. 2011 Feb 1;25(1):13-25 [PMID: 21090841]
  4. Blood. 2014 May 1;123(18):2791-6 [PMID: 24553177]
  5. Blood. 2010 Jun 3;115(22):4393-402 [PMID: 20194898]
  6. J Immunol. 2006 Jul 1;177(1):362-71 [PMID: 16785532]
  7. Br J Haematol. 2016 Mar;172(5):735-44 [PMID: 26659815]
  8. Blood Adv. 2020 Oct 27;4(20):5089-5092 [PMID: 33085756]
  9. N Engl J Med. 2012 Aug 30;367(9):826-33 [PMID: 22931316]
  10. Blood. 2020 Oct 29;136(18):2038-2050 [PMID: 32731259]
  11. N Engl J Med. 2018 Jun 21;378(25):2399-2410 [PMID: 29856685]
  12. Blood. 2014 Jul 24;124(4):503-10 [PMID: 24859363]
  13. Semin Oncol. 2003 Apr;30(2):146-52 [PMID: 12720125]
  14. Blood. 2017 Jan 26;129(4):456-459 [PMID: 27872060]
  15. Leuk Lymphoma. 2017 Jun;58(6):1506-1508 [PMID: 27724158]
  16. Blood. 2016 Jul 21;128(3):384-94 [PMID: 27222480]
  17. Medicine (Baltimore). 2010 Sep;89(5):308-318 [PMID: 20827108]
  18. Oncotarget. 2016 Jan 19;7(3):2809-22 [PMID: 26646452]
  19. Blood. 2014 Mar 13;123(11):1637-46 [PMID: 24366360]
  20. Clin Lymphoma. 2002 Dec;3(3):163-6 [PMID: 12521393]
  21. Clin Lymphoma Myeloma Leuk. 2017 May;17(5):252-262 [PMID: 28366781]
  22. Blood. 2000 Jun 15;95(12):3900-8 [PMID: 10845926]
  23. Ann Oncol. 2005 Jan;16(1):132-8 [PMID: 15598950]
  24. MAbs. 2015;7(2):311-21 [PMID: 25760767]
  25. Ann Oncol. 2006 Mar;17(3):488-94 [PMID: 16357024]
  26. Oncoimmunology. 2012 Jan 1;1(1):103-105 [PMID: 22720225]
  27. J Clin Oncol. 2002 May 1;20(9):2327-33 [PMID: 11981004]
  28. Leukemia. 2015 Jan;29(1):169-76 [PMID: 24912431]
  29. Immunol Rev. 2000 Jun;175:120-7 [PMID: 10933597]
  30. Blood. 2004 Nov 1;104(9):2635-42 [PMID: 15226177]
  31. Leuk Lymphoma. 2004 Oct;45(10):2047-55 [PMID: 15370249]
  32. Br J Haematol. 2015 Mar;168(5):701-7 [PMID: 25371371]
  33. Lancet Haematol. 2020 Nov;7(11):e827-e837 [PMID: 33091356]
  34. Br J Haematol. 2018 Apr;181(1):77-85 [PMID: 29468652]
  35. Blood Adv. 2021 May 11;5(9):2438-2446 [PMID: 33961019]
  36. Br J Haematol. 2011 Aug;154(3):357-62 [PMID: 21615385]
  37. J Clin Oncol. 2007 Aug 1;25(22):3344-9 [PMID: 17577016]
  38. Nat Rev Cancer. 2015 Jun;15(6):361-70 [PMID: 25998715]
  39. Oncoimmunology. 2014 Dec 13;3(9):e955684 [PMID: 25941618]
  40. Blood. 2004 Sep 15;104(6):1793-800 [PMID: 15172969]
  41. Blood. 2009 Apr 16;113(16):3673-8 [PMID: 19015393]
  42. Blood Adv. 2020 Aug 25;4(16):3952-3959 [PMID: 32822482]
  43. N Engl J Med. 2021 Jul 1;385(1):46-58 [PMID: 34192431]
  44. Nat Rev Cancer. 2012 Mar 22;12(4):278-87 [PMID: 22437872]
  45. N Engl J Med. 2012 May 24;366(21):2008-16 [PMID: 22621628]
  46. Lancet Haematol. 2017 Jan;4(1):e24-e34 [PMID: 27914971]
  47. J Clin Oncol. 2022 Jan 1;40(1):40-51 [PMID: 34388022]
  48. J Clin Oncol. 2010 May 1;28(13):2233-8 [PMID: 20368573]
  49. Expert Rev Clin Immunol. 2019 Apr;15(4):383-389 [PMID: 30580638]
Journal Article
Article has an altmetric score of 10

Word Cloud

Created with Highcharts 10.0.0antibodiesMonoclonalWaldenström'smacroglobulinemiamonoclonalWMestablishedRituximabtherapiesimportantroletreatmentarmamentariumhematologicalmalignanciesincludinganti-CD20antibodystandardtherapyuniquelowgradelymphomadueeffectivenesssafetymonotherapycombinationchemotherapytargetedNewertargetingCD20surfaceantigensshowneffectivepatientscurrentreviewattemptprovideoverviewmechanismsactiondiscussclinicalevidencesupportusetherapeuticpotentialantibody-based

Similar Articles

Cited By